Diastolic strain time as predictor for systolic dysfunction among patients with active breast cancer

Aviram Hochstadt, Joshua Arnold, Roni Rosen, Chen Sherez, Jack Sherez, Liat Mor, Matthew Derakhshesh, Yonatan Moshkovits, Ilan Merdler, Yaron Arbel, Livia Kapusta, Zach Rozenbaum, Yan Topilsky, Michal Laufer-Perl*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Although diastolic dysfunction is common among patients treated with cancer therapy, no clear evidence has been shown that it predicts systolic dysfunction. This study evaluated the correlation of diastolic strain time (Dst) with the routine echocardiography diastolic parameters and estimated its role in the early detection of cardiotoxicity among patients with active breast cancer. Methods: Data were collected as part of the Israel Cardio-Oncology Registry (ICOR), a prospective registry enrolling all adult patients referred to the cardio-oncology clinic. All patients with breast cancer, planned for Doxorubicin therapy, were included. Echocardiography, including global longitudinal systolic strain (GLS) and Dst, was assessed at baseline before chemotherapy (T1), during Doxorubicin therapy (T2) and after the completion of Doxorubicin therapy (T3). Cardiotoxicity was determined by GLS relative reduction of ≥15%. Dst was assessed as the time measured (ms) of the myocardium lengthening during diastole. Results: Among 69 patients, 67 (97.1%) were females with a mean age of 52 ± 13 years. Dst was significantly associated with the routine diastolic parameters. Significant GLS reduction was observed in 10 (20%) patients at T3. Both in a univariate and a multivariate analyses, the change in Ds basal time from T1 to T2 emerged to be significantly associated with GLS reduction at T3 (P <.04). Conclusions: Among breast cancer patients, Dst showed high correlation to the routine diastolic echocardiography parameters. Change in Ds basal time emerged associated with clinically significant systolic dysfunction as measured by GLS reduction.

Original languageEnglish
Pages (from-to)1890-1896
Number of pages7
Issue number11
StatePublished - Nov 2020


FundersFunder number
Pfizer pharmaceuticals Israel Ltd


    • cardio-oncology
    • cardiotoxicity
    • diastolic strain
    • global longitudinal strain


    Dive into the research topics of 'Diastolic strain time as predictor for systolic dysfunction among patients with active breast cancer'. Together they form a unique fingerprint.

    Cite this